Drug intelligence / Profile preview

amoxicillin + ciprofloxacin + doxycycline + methylprednisolone + metronidazole + vancomycin

Development stage
Unknown
Lead developer
GSK
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral, Intravenous, Intramuscular, Topical, Ophthalmic, Otic, Intraarticular, Vaginal
01

Overview

This is a combination of six drugs—amoxicillin, ciprofloxacin, doxycycline, methylprednisolone, metronidazole, and vancomycin. Each component has a distinct mechanism of action and therapeutic use: - Amoxicillin is a penicillin-type beta-lactam antibiotic that inhibits bacterial cell wall synthesis. - Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. - Doxycycline is a tetracycline-class antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit. - Methylprednisolone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive effects via glucocorticoid receptor agonism. - Metronidazole is an antimicrobial agent effective against anaerobic bacteria and protozoa; it disrupts DNA structure after reduction in susceptible organisms[7][10]. - Vancomycin is a glycopeptide antibiotic that inhibits cell wall biosynthesis in Gram-positive bacteria. Such an extensive combination would be highly unusual in clinical practice due to overlapping spectra, increased risk of adverse effects, drug interactions, and lack of evidence for combined efficacy. Some combinations (e.g., metronidazole plus vancomycin) have been studied for severe infections like Clostridioides difficile infection but are not generally superior to monotherapy[6][9]. This specific six-drug regimen does not correspond to any approved or standard therapy.

02

Targets

Bacterial RibosomeTopo IV (Bacterial Topoisomerase IV)D-Ala-D-Ala (D-Ala-D-Ala terminus)GR (Glucocorticoid receptor)DNA gyrasePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on amoxicillin + ciprofloxacin + doxycycline + methylprednisolone + metronidazole + vancomycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amoxicillin + ciprofloxacin + doxycycline + methylprednisolone + metronidazole + vancomycin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call